MARKET

AVXL

AVXL

Anavex Life Scie
NASDAQ
3.780
-0.020
-0.53%
After Hours: 3.780 0 0.00% 18:34 04/19 EDT
OPEN
3.760
PREV CLOSE
3.800
HIGH
3.800
LOW
3.600
VOLUME
2.08M
TURNOVER
0
52 WEEK HIGH
10.45
52 WEEK LOW
3.600
MARKET CAP
310.39M
P/E (TTM)
-7.0575
1D
5D
1M
3M
1Y
5Y
Class Action Lawsuit against Anavex Life Sciences (NASDAQ:AVXL)
TipRanks · 3d ago
Weekly Report: what happened at AVXL last week (0408-0412)?
Weekly Report · 6d ago
Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL
Barchart · 6d ago
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Anavex Life Sciences Corp. Will present at the Noble Capital Markets Virtual Healthcare Equity Conference on April 18th, 2024. Anavex is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.
Barchart · 04/11 06:30
Weekly Report: what happened at AVXL last week (0401-0405)?
Weekly Report · 04/08 09:10
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Anavex Life Sciences's (NASDAQ:AVXL) cash burn rate is up 10% in the last year. The company is burning through cash to fund its growth. Its cash runway is 4.9 years from December 2023. Anavex life Sciences doesn't record any revenue over the past year. It's an early stage company and may need to raise more cash to grow its business.
Simply Wall St · 04/01 10:38
Weekly Report: what happened at AVXL last week (0325-0329)?
Weekly Report · 04/01 09:10
AVXL STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights and Remedies Against Anavex Life Sciences Corporation
Robbins LLP reminds investors that a shareholder filed a class action on behalf of Anavex Life Sciences Corporation (NASDAQ: AVXL) An avex shareholder alleges the company misled investors about the likelihood of success of its clinical trial. You may be eligible to participate in the class action against anavex life sciences corporation.
Barchart · 03/31 00:46
More
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Webull offers Anavex Life Sciences Corp stock information, including NASDAQ: AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.